Even if a biotech has a super drug and bad management there is plenty of grief for the company and shareholders.
Good management: AMGN, BIIB, CELG, GILD, SGEN. You see the results
The rest are either greedy (just to make money for themselves and screw shareholders) and/or incompetent.
As for the CLVS stock, it is priced with some premium. CLVS has no partners, so it has everything for itself. It also has no options for naked speculations.